- Home
- ODYS vs QNTM Comparison
ODYS vs QNTM Comparison
Compare ODYS & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODYS
- QNTM
- Stock Information
- Founded
- ODYS N/A
- QNTM 1998
- Country
- ODYS Israel
- QNTM Canada
- Employees
- ODYS N/A
- QNTM N/A
- Industry
- ODYS
- QNTM
- Sector
- ODYS
- QNTM
- Exchange
- ODYS NYSE
- QNTM NYSE
- Market Cap
- ODYS 76.7M
- QNTM 69.3M
- IPO Year
- ODYS N/A
- QNTM N/A
- Fundamental
- Price
- ODYS $4.62
- QNTM $25.15
- Analyst Decision
- ODYS Strong Buy
- QNTM
- Analyst Count
- ODYS 1
- QNTM 0
- Target Price
- ODYS $10.00
- QNTM N/A
- AVG Volume (30 Days)
- ODYS 12.3K
- QNTM 188.7K
- Earning Date
- ODYS 08-11-2025
- QNTM 08-13-2025
- Dividend Yield
- ODYS N/A
- QNTM N/A
- EPS Growth
- ODYS N/A
- QNTM N/A
- EPS
- ODYS N/A
- QNTM N/A
- Revenue
- ODYS $5,842,000.00
- QNTM N/A
- Revenue This Year
- ODYS N/A
- QNTM N/A
- Revenue Next Year
- ODYS N/A
- QNTM N/A
- P/E Ratio
- ODYS N/A
- QNTM N/A
- Revenue Growth
- ODYS 100.27
- QNTM N/A
- 52 Week Low
- ODYS $4.00
- QNTM $2.70
- 52 Week High
- ODYS $10.80
- QNTM $38.25
- Technical
- Relative Strength Index (RSI)
- ODYS N/A
- QNTM 61.07
- Support Level
- ODYS N/A
- QNTM $21.63
- Resistance Level
- ODYS N/A
- QNTM $24.61
- Average True Range (ATR)
- ODYS 0.00
- QNTM 2.37
- MACD
- ODYS 0.00
- QNTM 0.27
- Stochastic Oscillator
- ODYS 0.00
- QNTM 91.60
About ODYS ODYSIGHT AI INC
Odysight ai Inc is engaged in the development, production, and marketing of Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.